Biodexa Pharmaceuticals (BDRX) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Biodexa Pharmaceuticals has successfully appealed a Nasdaq delisting decision, securing an extension to meet the $1.00 minimum bid price requirement. This development provides the company with additional time to stabilize its stock price, crucial for its continued Nasdaq listing. Investors will be watching closely as Biodexa works towards compliance by the end of October 2024.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
